Antidote competitors

Antidote Competitors include Amarin, Sucampo Pharmaceuticals, BTG and Zogenix.
Add company...
Antidote
Antidote
Antidote is accelerating the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.
Amarin
Amarin
Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.
Sucampo Pharmaceuticals
Sucampo Pharmaceuticals
Sucampo is a global biopharmaceutical company focused on the development and commercialization of medicines based on prostones, to meet the major unmet medical needs of patients on a global basis.
BTG
BTG
BTG is an international specialist healthcare company.
Zogenix
Zogenix
Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.
Founding Date
Founding Date
2009
Founding Date
1991
Founding Date
1996
Founding Date
1948
Founding Date
2006
Type
Type
Private
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Tags
Locations
Locations
London, GB HQ
New York, US
Carmel, US
Locations
Dublin, IE HQ
Bedminster Township, US
Locations
Rockville, US HQ
Sanda Shi, JP
Kita Ward, JP
Chuo Ward, JP
Chiyoda, JP
Zug, CH
Milton, GB
Locations
London, GB HQ
Rosedale, AU
Ottawa, CA
Düsseldorf, DE
Hong Kong , HK
Ataşehir, TR
Ffostrasol, GB
see more
Locations
Emeryville, US HQ
Windsor And Maidenhead, GB
Employees
Employees
623% decrease
Employees
24112% increase
Employees
139
Employees
N/A
Employees
681% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
5.6 b
Valuation ($)
1.2 b
Valuation ($)
N/A
Valuation ($)
1.8 b
Twitter followers
Twitter followers
1
Twitter followers
N/A
Twitter followers
242
Twitter followers
786
Twitter followers
475

Financial

Revenue (est.)
Revenue (est.)
£2.2m (FY, 2017)
Revenue (est.)
$181.1m (FY, 2017)
Revenue (est.)
$230.1m (FY, 2016)
Revenue (est.)
£620.5m (FY, 2018)
Revenue (est.)
$9.8m (FY, 2017)
Cost of goods
Cost of goods
£892.3k (FY, 2017)
Cost of goods
$45m (FY, 2017)
Cost of goods
$76m (FY, 2016)
Cost of goods
£185.9m (FY, 2018)
Cost of goods
$10.7m (FY, 2017)
Gross profit
Gross profit
£1.3m (FY, 2017)
Gross profit
$136.2m (FY, 2017)
Gross profit
$154.1m (FY, 2016)
Gross profit
£434.6m (FY, 2018)
Gross profit
($908k) (FY, 2017)
Net income
Net income
(£4.6m) (FY, 2017)
Net income
($67.9m) (FY, 2017)
Net income
$18.5m (FY, 2016)
Net income
£12.7m (FY, 2018)
Net income
($126.8m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 17.9m
Total funding raised
$ 70m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Amarin
HQ
Dublin, IE
Employees
241↑ 12% increase

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.

View company
Sucampo Pharmaceuticals
HQ
Rockville, US
Employees
139

Sucampo is a global biopharmaceutical company focused on the development and commercialization of medicines based on prostones, to meet the major unmet medical needs of patients on a global basis.

View company
BTG
HQ
London, GB

BTG is an international specialist healthcare company.

View company
Zogenix
HQ
Emeryville, US
Employees
68↑ 1% increase

Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.

View company